- Home
- MHUA vs ERNA Comparison
MHUA vs ERNA Comparison
Compare MHUA & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- ERNA
- Stock Information
- Founded
- MHUA 1990
- ERNA 2018
- Country
- MHUA China
- ERNA United States
- Employees
- MHUA N/A
- ERNA N/A
- Industry
- MHUA Medical Specialities
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- ERNA Health Care
- Exchange
- MHUA Nasdaq
- ERNA Nasdaq
- Market Cap
- MHUA 11.8M
- ERNA 10.2M
- IPO Year
- MHUA 2022
- ERNA N/A
- Fundamental
- Price
- MHUA $0.42
- ERNA $1.18
- Analyst Decision
- MHUA
- ERNA
- Analyst Count
- MHUA 0
- ERNA 0
- Target Price
- MHUA N/A
- ERNA N/A
- AVG Volume (30 Days)
- MHUA 147.2K
- ERNA 83.1K
- Earning Date
- MHUA 09-19-2025
- ERNA 11-11-2025
- Dividend Yield
- MHUA N/A
- ERNA N/A
- EPS Growth
- MHUA N/A
- ERNA N/A
- EPS
- MHUA 0.40
- ERNA N/A
- Revenue
- MHUA $96,909,642.00
- ERNA $488,000.00
- Revenue This Year
- MHUA N/A
- ERNA N/A
- Revenue Next Year
- MHUA N/A
- ERNA N/A
- P/E Ratio
- MHUA $1.22
- ERNA N/A
- Revenue Growth
- MHUA N/A
- ERNA 201.24
- 52 Week Low
- MHUA $0.25
- ERNA $1.18
- 52 Week High
- MHUA $1.24
- ERNA $22.80
- Technical
- Relative Strength Index (RSI)
- MHUA 52.84
- ERNA 32.55
- Support Level
- MHUA $0.39
- ERNA $1.19
- Resistance Level
- MHUA $0.50
- ERNA $1.57
- Average True Range (ATR)
- MHUA 0.04
- ERNA 0.14
- MACD
- MHUA 0.00
- ERNA 0.01
- Stochastic Oscillator
- MHUA 49.53
- ERNA 2.50
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.